98%
921
2 minutes
20
Introduction/aims: Nusinersen intrathecal administration can be challenging in spinal muscular atrophy (SMA) adults. We aimed to determine if the ultrasound (US)-assistance reduces the number of needle attempts and needle redirections needed for intrathecal drug administration and its impact on the procedure time, the incidence of adverse events (AEs), and patient satisfaction in these patients.
Methods: Fifty-eight patients aged 18 years and older scheduled for intrathecal nusinersen injection were enrolled and randomized (1:1 ratio) into Group 1 (nusinersen infusion with US-assisted technique) or Group 2 (nusinersen infusion with landmark-based technique). The number of attempts, number of redirections, periprocedural time, AEs and patient satisfaction were reported. Continuous variables were compared with the Student t-test or Wilcoxon rank sum test. Categorical variables were evaluated with the Chi-square test or Fisher's exact test in case of expected frequencies <5. The p-values <.05 were considered statistically significant.
Results: There were no statistical differences in the number of attempts, AEs, or patient satisfaction between the two groups. The number of needle redirections was significantly lower in the ultrasound group versus landmark-based group (p < .05) in both the overall group of patients and in the subgroup with difficult spines. The periprocedural time was about 40 seconds longer in US-group versus landmark-based group (p < .05).
Discussion: In SMA adults, US assistance reduces the number of needle redirections needed for intrathecal drug administration. These results suggest that the US assistance may be advantageous for nusinersen therapy to reduce the therapeutic burden of intrathecal infusion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/mus.28248 | DOI Listing |
Am J Phys Med Rehabil
September 2025
Department of Neurosurgery, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Objective: This study aims to compare the long-term results of cITB rehabilitation against those of conventional treatment for intractable spasticity in children with cerebral palsy using the International Classification of Functioning, Disability and Health of Children and Youth (ICF-CY).
Design: 5-year single-center retrospective cohort study.
Results: The ICF-CY data from 24 patients with CP of GMFCS levels IV-V (aged between 8 and 18 years) were retrospectively analyzed for 5 years.
Nucleic Acids Res
August 2025
Roche Pharma Research and Early Development, Neuroscience and Rare Disease discovery and translational area, Roche Innovation Center Basel, Basel 4070, Switzerland.
Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by the loss of neuronal ubiquitin E3 ligase UBE3A, with no available treatment. Restoring UBE3A by downregulating the paternally cis-acting long noncoding antisense transcript (UBE3A-ATS) is a potentially disease modifying strategy. However, developing molecules targeting human UBE3A-ATS is challenging due to its selective expression in mature neurons and lack of sequence conservation across species.
View Article and Find Full Text PDFLife Sci
August 2025
Division of Physiology and Anatomy, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Aims: Gabapentin reduces bladder pain and overactivity in lipopolysaccharide (LPS)-induced chronic cystitis in a rat model. This study evaluated the role of the spinal cord and the descending noradrenergic pathway in the effects of mirogabalin (MGB), a novel gabapentinoid drug on painful bladder hypersensitivity in this model.
Main Methods: Chronic cystitis was induced in female Sprague-Dawley rats via repeated intravesical LPS instillation.
Int J Obstet Anesth
July 2025
Department of Anesthesiology, Columbia University Irving Medical Center, New York, USA. Electronic address:
Background: Off-label use of intrathecal dexmedetomidine (ITDex) is suggested in recent guidelines for pain management during cesarean delivery. The primary objective of this scoping review was to identify all publications reporting on ITDex for cesarean delivery, and secondarily to evaluate the evidence and characterize reported outcomes associated with its use.
Methods: Following PRISMA-Scr guidelines, we searched PubMed and Embase in October 2024 for articles reporting on ITDex for cesarean delivery and conducted a scoping review on randomized controlled trials (RCTs) and observational trials.
Neurodegener Dis Manag
August 2025
Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, Tehran, Iran.
Introduction: There are a few therapeutic approaches for Amyotrophic Lateral Sclerosis (ALS) which can only slow down or stop the disease progression for a limited period of time. Since it has been proven that Mesenchymal Stromal Cells (MSCs) produce neurotrophic factors and have some neuroprotective effects, stem cell therapy has been proposed as an alternative or add-on treatment for ALS patients.
Method & Material: In this open-label clinical trial, two-repeated dose of 60 million GMP compliant Wharton's Jelly-derived Mesenchymal Stromal Cells (WJ-MSCs) were transplanted intrathecally (#6 patients) or intravenously (#6 patients) twice with a 3-month interval.